2-[(4S)-4-amino-5-oxopentyl]guanidine

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 2-[(4S)-4-amino-5-oxopentyl]guanidine
• 英文别名: 2-(4-amino-5-oxopentyl)guanidine
• 化学式: C₆H₁₄N₄O
• 分子量: 158.2
• InChiKey: QJYRUYURLPTHLR-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -2
• 重原子数：
  11
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.67
• 拓扑面积：
  108
• 氢给体数：
  3
• 氢受体数：
  3

文献信息

• TUBULYSIN CONJUGATE FOR USE IN TREATING CANCER
  申请人：ENDOCYTE, INC.

  公开号：US20170348376A1

  公开（公告）日：2017-12-07

  The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating folate receptor-expressing cancers with a folate-tubulysin conjugate. The invention described herein also relates to methods of treating folate-expressing cancers with a folate tubulysin conjugate in patients where stable disease results after treatment with the folate-tubulysin conjugate.

  本发明涉及用于靶向治疗的药物传递共轭物。本发明涉及使用叶酸-管芽霉素共轭物治疗表达叶酸受体的癌症的方法。本发明还涉及在使用叶酸-管芽霉素共轭物治疗后导致稳定疾病的患者中治疗表达叶酸的癌症的方法。
• [EN] CONJUGATES FOR TREATING DISEASES CAUSED BY PSMA EXPRESSING CELLS<br/>[FR] CONJUGUÉS POUR TRAITER LES MALADIES PROVOQUÉES PAR DES CELLULES EXPRIMANT PSMA
  申请人：ENDOCYTE INC

  公开号：WO2014078484A1

  公开（公告）日：2014-05-22

  The invention described herein pertains to the diagnosis, imaging, and/or treatment of pathogenic cell populations. In particular, the invention described herein pertains to the diagnosis, imaging, and/or treatment of diseases caused by PSMA expressing cells, such as prostate cancer cells, using compounds capable of targeting PSMA expressing cells.

  本发明涉及对病原细胞群体进行诊断、成像和/或治疗。具体来说，本发明涉及利用能够靶向PSMA表达细胞的化合物对由PSMA表达细胞引起的疾病，如前列腺癌细胞，进行诊断、成像和/或治疗。
• [EN] METHODS OF TREATING CANCER WITH TUBULYSIN CONJUGATES<br/>[FR] PROCÉDÉS DE TRAITEMENT DU CANCER AVEC DES CONJUGUÉS DE TUBULYSINE
  申请人：ENDOCYTE INC

  公开号：WO2016049313A1

  公开（公告）日：2016-03-31

  The invention described herein pertains to drug delivery conjugates for targeted therapy. The invention described herein relates to methods of treating folate receptor-expressing cancers with a folate-tubulysin conjugate. The invention described herein also relates to methods of treating folate-expressing cancers with a folate tubulysin conjugate in patients where stable disease results after treatment with the folate-tubulysin conjugate.

  本发明涉及用于靶向治疗的药物传递共轭物。本发明涉及使用叶酸-管芋霉素共轭物治疗叶酸受体表达的癌症的方法。本发明还涉及在使用叶酸-管芋霉素共轭物治疗后导致稳定疾病的患者中治疗叶酸表达的癌症的方法。
• Polyamide analogs
  申请人：——

  公开号：US20020198254A1

  公开（公告）日：2002-12-26

  This invention is directed to novel antibacterial/antifungal/antiparasitic agents of Formula (I): 1 pharmaceutical compositions containing them, methods for their use and methods for preparing these compound

  这项发明涉及具有以下结构的新型抗菌/抗真菌/抗寄生虫剂（I）：1药物组合物，包含它们，以及使用它们的方法和制备这些化合物的方法。
• Vitamin-Receptor Binding Drug Delivery Conjugates
  申请人：Endocyte, Inc.

  公开号：US20160220694A1

  公开（公告）日：2016-08-04

  The invention describes a vitamin receptor binding drug delivery conjugate, and preparations therefor. The drug delivery conjugate consists of a vitamin receptor binding moiety, a bivalent linker (L), and a drug. The vitamin receptor binding moiety includes vitamins, and vitamin receptor binding analogs and derivatives thereof, and the drug includes analogs and derivatives thereof. The vitamin receptor binding moiety is covalently linked to the bivalent linker, and the drug, or the analog or the derivative thereof, is covalently linked to the bivalent linker, wherein the bivalent linker (L) includes components such as spacer linkers, releasable linkers, and heteroatom linkers, and combinations thereof. Methods and pharmaceutical compositions for eliminating pathogenic cell populations using the drug delivery conjugate are also described.

  该发明描述了一种维生素受体结合药物传递共轭物及其制备方法。药物传递共轭物由维生素受体结合基团、双价连接剂（L）和药物组成。维生素受体结合基团包括维生素、维生素受体结合类似物及其衍生物，药物包括类似物及其衍生物。维生素受体结合基团与双价连接剂共价连接，药物或其类似物或衍生物与双价连接剂共价连接，其中双价连接剂（L）包括间隔连接剂、可释放连接剂和杂原子连接剂以及其组合。还描述了利用该药物传递共轭物消除病原细胞群的方法和药物组合物。